ScholarGate
Get started
Process / pipelineObstetrics GynecologyMenopause-symptomsPipeline

Menopause-Specific Quality of Life Questionnaire

Also known as: MENQOL, Menopause Quality of Life

OriginatorHilditch, J. R., Lewis, J., Peter, A., van Maris, B., Ross, A., Franssen, E., Guyatt, G. H.Year1996Sources1Related methods6

The Menopause-Specific Quality of Life Questionnaire (MENQOL) is a 29-item self-report instrument designed to assess quality of life in women experiencing menopausal symptoms. Developed by Hilditch and colleagues in 1996, the MENQOL captures four interrelated symptom domains: vasomotor symptoms (hot flushes, night sweats), psychosocial symptoms (mood, stress, anxiety), physical symptoms (fatigue, aches, sleep), and sexual symptoms. It is the primary menopause-specific outcome measure used in hormone replacement therapy trials and menopause research.

Key highlights

  • Comprehensive disease-specific design capturing four symptom dimensions central to menopausal health, superior to generic quality-of-life scales.
  • Developed using rigorous methodology (patient input, expert panel, extensive psychometric validation) ensuring clinical relevance.
  • Dimensional domain structure enabling identification of predominant symptom profile, guiding personalized treatment matching.
  • Highly responsive to treatment; significant MENQOL improvement documented following HRT, SSRIs, and behavioral interventions.
  • Extensively used and validated internationally; normative data available in multiple populations and cultures.

Intuition

This section is available to Pro members. Upgrade to Pro

How it works

This section is available to Pro members. Upgrade to Pro

When to use it

The MENQOL is appropriate for comprehensive assessment at the time of menopause symptom onset, providing baseline severity across symptom domains. It is valuable for monitoring symptom response in women using hormone replacement therapy (HRT), selective serotonin reuptake inhibitors (SSRIs), or behavioral interventions, with serial MENQOL measurement (baseline, 8 weeks, 12 weeks, 6 months) documenting treatment efficacy. The MENQOL is standard in menopausal health research and in shared decision-making discussions about HRT or other symptom management. It is appropriate across the full menopausal transition (perimenopause to postmenopause).

Strengths & limitations

Strengths
  • Comprehensive disease-specific design capturing four symptom dimensions central to menopausal health, superior to generic quality-of-life scales.
  • Developed using rigorous methodology (patient input, expert panel, extensive psychometric validation) ensuring clinical relevance.
  • Dimensional domain structure enabling identification of predominant symptom profile, guiding personalized treatment matching.
  • Highly responsive to treatment; significant MENQOL improvement documented following HRT, SSRIs, and behavioral interventions.
  • Extensively used and validated internationally; normative data available in multiple populations and cultures.
Limitations
  • Intended for women experiencing menopausal symptoms; less appropriate for asymptomatic postmenopausal women.
  • Does not assess all possible menopausal symptoms (e.g., skin changes, hair changes, joint inflammation); limited to 29 items.
  • Relies entirely on subjective self-report; does not incorporate objective measures (hot flush frequency via wrist monitor, estradiol levels).
  • Validation is primarily in perimenopausal and early postmenopausal women; applicability to late postmenopause (>10 years) is less established.

Common pitfalls

This section is available to Pro members. Upgrade to Pro

Applications

This section is available to Pro members. Upgrade to Pro

Frequently asked

Can I use MENQOL before my periods stop?

Yes. MENQOL is appropriate during perimenopause (when periods are becoming irregular) through all postmenopausal years. It is designed to capture symptoms across the full menopausal transition, not just after the final period.

What score indicates that I need hormone replacement therapy?

MENQOL does not determine HRT need; rather, clinical assessment and individual discussion of risks/benefits determine treatment appropriateness. A high Vasomotor domain score suggests HRT might be considered. However, total MENQOL score alone does not dictate treatment. Discuss your symptoms and treatment options with your healthcare provider.

Can MENQOL measure treatment response?

Yes, MENQOL is responsive to treatment. Most women receiving HRT, SSRIs, or behavioral interventions show significant MENQOL improvement within 8-12 weeks. Your clinician may readminister MENQOL periodically to document your symptom response and guide treatment adjustment.

Are there different versions of MENQOL?

The original MENQOL has 29 items. A shorter version, MENQOL Intervention Trial (MENQOL-IT), includes 28 items and is designed specifically for intervention trials. Both are valid; use the version appropriate to your clinical or research context.

Sources

  1. 1.
    Hilditch, J. R., Lewis, J., Peter, A., van Maris, B., Ross, A., Franssen, E., Guyatt, G. H., Lethargy, S., & Improvement, T. (1996). A menopause-specific quality of life questionnaire: development and psychometric properties. Maturitas, 24(3), 161-175.
    DOI 10.1016/S0378-5122(96)82006-8

You have read it. What now?

Ask about this methodSimilar methods

Cite this page

ScholarGate. (2026, June 3). Menopause-Specific Quality of Life Questionnaire. ScholarGate. https://scholargate.app/obstetrics-gynecology/menopause-specific-qol

Menopause-Specific Quality of Life Questionnaire | ScholarGate